Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

nChroma Bio

Request full access

Advancing targeted genetic medicine with safe, precise in vivo delivery, focusing on liver therapies like CRMA-1001 to address chronic hepatitis B and D using epigenetics

Boston, United StatesFounded 2024Biotech & Life Sciences

About nChroma Bio

nChroma Bio emerged in December 2024 from the strategic merger of two Boston-area biotechnology firms, Chroma Medicine and Nvelop Therapeutics. This union created a company focused on advancing in vivo targeted genetic medicines, combining Chroma's expertise in epigenetic editing with Nvelop's non-viral, programmable delivery technologies. Concurrent with its formation, nChroma Bio secured $75 million in an oversubscribed financing round led by prominent investors including Cormorant Asset Management, ARCH Venture Partners, Atlas Venture, and Newpath Partners, providing a multi-year operational runway.

The company operates in the biotechnology sector, specifically focusing on the development of genetic medicines to address a wide range of diseases with high unmet needs. Its business model centers on the research and development of therapeutic candidates, with a strategy that includes forming strategic partnerships with healthcare institutions and pharmaceutical companies to accelerate product development and expand market reach. The leadership team is helmed by CEO Jeff Walsh, who previously led Nvelop Therapeutics, and Jeff Marrazzo, co-founder of Spark Therapeutics, serves as the Chairman of the Board.

nChroma Bio's core technology is a modular platform that pairs therapeutic payloads with targeted delivery systems. A key differentiator is its use of epigenetic editing, a process that modulates gene expression by adding chemical tags to DNA without cutting or altering the underlying genetic sequence. This approach aims to mitigate risks associated with traditional gene-editing techniques, such as genomic rearrangements. For delivery, the company utilizes lipid nanoparticles (LNPs) for liver-specific targets and is developing engineered virus-like particles (eVLPs) for tissues outside of the liver. The lead program, CRMA-1001, is a liver-targeted epigenetic editor being developed as a potential functional cure for chronic hepatitis B and D. Preclinical studies have shown that CRMA-1001 can achieve a durable reduction of key viral biomarkers. The company plans to submit a clinical trial application for CRMA-1001 in 2025 and anticipates patient dosing to begin in 2026.

Source: Dealroom company data

At a glance

Status
Operational
Employees
64
Open positions
1
Dealroom signal
36.8/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Genetics and genomics, Epigenetics, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Investment activity
2 companies
Capital deployed
—
Preferred round
Unknown

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing Dec 2024 $75M $300M Sofinnova Partners · Wellington Management · 5AM Ventures · Casdin Capital ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

nChroma Bio website traffic

Latest recorded traffic for nChroma Bio is 2.3K monthly website visits, up 53.3% over the last three months. nChroma Bio's team declined 3% over the past year.

Latest monthly visits2.3K 3-month web change+53.3% 1-year team growth-3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

nChroma Bio in the Boston ecosystem

Live from Dealroom

The nChroma Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

19 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A19 investors entered at this stage

Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See nChroma Bio’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.